. 2022 Mar 5;70:103219. doi: 10.1016/j.jddst.2022.103219

Table 8.

Nanostructures in clinical studies from 2018 to the present.

Nanostructure	Drug	Disease	Phase	Administration Route	ClinicalTrials.gv Identifier
Polymeric nanoparticles	N/A	SARS-CoV-2	N/A	N/A	NCT04490200
Micelle	PTX	NSCLC	Phase 1	Intravenous	NCT04778839
Liposome	Irinotecan	Small cell lung cancer	Phase 2	Intravenous	NCT04727853
Liposome	Amphotericin B	Invasive pulmonary aspergillosis	Phase 1	Inhalation (nebulization)	NCT04267497
Liposome	Amikacin	Mycobacterium fnfections, nontuberculous	Phase 3	Inhalation (nebulization)	NCT04677569
Liposome	Cyclosporine A	Bronchiolitis obliterans and lung transplant rejection	Phase 3	Inhalation (nebulization)	NCT03657342
Liposome	Amphotericin B	Pulmonary mucormycosis	Phase 2	Intravenous	NCT04502381
Liposome	Lactoferrin	SARS-CoV-2	Phase 2/Phase 3	Oral and intranasal	NCT04475120
Lipid based nanoparticles	Quaratusugene ozeplasmid	Lung cancer	Phase 1/Phase 2	Intravenous	NCT04486833
Lipid based nanoparticles	SARS-CoV-2 wild-type S-spike mRNA	SARS-CoV-2	Phase 1	Intramuscular	NCT04566276
Exosomes	Human adipose-derived mesenchymal progenitor cell exosomes	Drug resistant lung infection (gram negative bacilli)	Phase 1/Phase 2	Inhalation (aerosol)	NCT04544215
Exosomes	Allogenic adipose mesenchymal stem cells derived exosomes	SARS-CoV-2	Phase 1	Inhalation	NCT04276987
Exosomes	SARS-CoV--2 specific T cell derived exosomes	SARS-CoV-2	Phase 1	Inhalation (aerosol)	NCT04389385